BiologicsFinancialSpineSports Medicine

Global Orthobiologics Market valued at $5.4 billion in 2021, is expected to witness a decent growth rate of 7% in the next 5 years

Medi-Tech Insights: Growing cases of sports injuries and road accidents, increasing geriatric and obese population globally, rising number of people suffering from arthritis and other spine-related disorders, growing patient preference for minimally invasive procedures, and mechanical advancements in biomaterials are some of the key factors driving the growth of the global orthobiologics market.

BRUSSELS, BELGIUM, Nov. 16, 2022 (GLOBE NEWSWIRE) —

Description:

Orthobiologics employs biomaterials and cell-based therapies to rapidly heal musculoskeletal injuries and support tissue healing and restoration through their regenerative potential. These products are derived from components that are naturally present in the body and interact dynamically with the musculoskeletal system to facilitate the healing of bone, cartilage, ligament, and diseased or injured meniscus & tendons.

Technological Advancements in Orthobiologics Market to Fuel its Global Market Demand

Consistent advancements in orthobiologics have enabled to develop efficient products with advanced patient healing capabilities and increased applications, among others. Such advancements tend to provide a competitive edge to all global manufacturers and therefore, all major players are continuously focusing on investing in research activities for new product development and expanding their geographic reach to strengthen their position in the orthobiologics market. Some of the technological advancements are listed below:

  • In June 2022, Istos Biologics launched the Influx Fibrant line of 100% cortical allograft products featuring a patented technology from TheraCell and designed to advance patient healing.
  • In March 2022, SeaSpine launched new orthobiologic products- NorthStar cervical facet fusion and Flash navigation lumbar facet fusion, with an aim to streamline reproducible procedural workflow while maximizing the area for fusion.
  • In September 2020, Cerapedics received approval for its i-FACTOR+ Matrix bone graft from Health Canada. This next-generation bone graft is based on P15 osteogenic cell-binding peptide that supports bone growth through cell attraction, attachment, and activation.

Get Detailed Insights on Orthobiologics Market with a Sample Report PDF https://meditechinsights.com/orthobiologics-market/

Key Growth Strategies Adopted by Leading Market Players operating in Orthobiologics Market

Leading market players working in the global orthobiologics market have adopted acquisition and partnership as key growth strategy to expand their product offerings, enhance their geographic presence & distribution capabilities, and to co-develop advanced products. Some of these developments are listed below-

  • In August 2022, Orthofix Medical Inc. entered in a strategic partnership with CGBio, a synthetic bone grafts developer, to co-develop and commercialize Novosis recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials and other tissue regenerative solutions for the Canadian and US markets.
  • In July 2021, Celularity Inc. and Arthrex, Inc. entered into a supply and distribution agreement for the distribution and commercialization of multiple products including placental-derived biomaterial products from Celularity for orthopaedics and sport medicine in the US.
  • In March 2021, SeaSpine Holdings Corporation entered in an agreement to acquire 7D Surgical, Inc., a Canada-based medical device company. This acquisition was aimed at combining spinal implant and orthobiologics portfolios to advance spine surgery.

Irrespective of the market challenges such as unfavorable reimbursement scenario and pricing pressure on market players, the global orthobiologics market is growing strongly and is expected to gain further momentum in the upcoming years due to a strong emphasis on spinal fusion segment, focus on demineralized bone putties with excipients, increasing usage of viscosupplements, and innovations addressing the entire procedure, among others.

For instance, during the forecast period, the viscosupplements segment is anticipated to be driven by advancements in hyaluronic acid-based therapies, rising prevalence of lifestyle-induced disorders, high effectiveness in delaying total knee replacement procedures, and growing preference for non-surgical treatments for osteoarthritis. Additionally, conventional techniques such as autograft and allograft are difficult to manage, painful for the patient, have fairly contrasting outcomes, and may require repeat surgeries. Hence, an easier-to-use solution is likely to be accepted by doctors and healthcare providers which has greater success rate from a medical and financial standpoint, providing opportunity for market players in this space.

Competitive Landscape Analysis: Orthobiologics Market

The global orthobiologics market is marked by the presence of established market players such as Medtronic Plc (Ireland); Zimmer Biomet Holdings, Inc. (US); Arthrex, Inc. (US); Bioventus (US); DePuy Synthes (Johnson & Johnson Services, Inc.) (US); Stryker Corporation (US); MTF Biologics (US); and others.

Get Customized Report on Orthobiologics Market https://meditechinsights.com/orthobiologics-market/

About Medi-Tech Insights:

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact Us:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button